American Oncology Network Azioni (OTC: AONC)

Ultime notizie per American Oncology Network (OTC:AONC) Azioni

American Oncology Network

American Oncology Network Inc through its subsidiary companies and variable interest entities, is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 37 oncology practices located in twenty states. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging.

AMER ONCOLOGY NETWORK A by American Oncology Network, Inc.

American Oncology Network Inc

American Oncology Network Inc Warrants (31/03/2028)

Citigroup analyst Piyush Avasthy maintains Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) with a Neutral and lowers the price target from $371 to $250.

News

Price Target

Analyst Ratings

ZBRA

Citigroup Maintains Neutral on Zebra Technologies, Lowers Price Target to $250

Citigroup analyst Andrew Kaplowitz maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy and lowers the price target from $152 to $134.

Citigroup Maintains Buy on Xylem, Lowers Price Target to $134

Citigroup analyst Andrew Kaplowitz maintains Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) with a Buy and lowers the price target from $45 to $36.

Citigroup Maintains Buy on Vontier, Lowers Price Target to $36

Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.80 by 5.56 percent. This is a 24.18 percent increase over earnings of $1.53 per share from the same period last year. The company reported quarterly sales of $462.85 million which missed the analyst consensus estimate of $478.54 million by 3.28 percent. This is a 8.11 percent increase over sales of $428.14 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

PNFP

Pinnacle Finl Partners Q1 Adj $1.90 Beats $1.80 Estimate, Sales $462.85M Miss $478.54M Estimate

Citigroup analyst Andrew Kaplowitz maintains Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Buy and lowers the price target from $153 to $98.

Citigroup Maintains Buy on Vertiv Holdings, Lowers Price Target to $98

Citigroup analyst Andrew Kaplowitz maintains Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) with a Neutral and lowers the price target from $116 to $100.

VLTO

Citigroup Maintains Neutral on Veralto, Lowers Price Target to $100

ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) shares are rising in extended trading Monday after the company withdrew its <a href="https://www.benzinga.com/pressreleases/25/04/b44801990/onsemi-withdraws-proposal-to-acquire-allegro-microsystems">acquisition proposal for Allegro MicroSystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>)</a>.
What Happened: After the market close on Monday, ON Semiconductor announced it ceased efforts to acquire Allegro MicroSystems and withdrew its all-cash proposal of $35.10 per share after determining there was &#8220;no actionable path forward.&#8221;
On Semi shares popped on the news, while Allegro MicroSystems shares traded lower by approximately 10%. 
ON Semiconductor said it will focus on other existing opportunities to enhance shareholder value. In connection with the announcement, the company said it intends to continue to allocate capital towards its existing buyback program.
&#8220;On Semi is committed to taking a disciplined approach to capital allocation and maximizing long-term stockholder value,&#8221; said Hassane El-Khoury, president and CEO of ON Semiconductor.
&#8220;While we continue to believe that a combination with onsemi would be beneficial to all stakeholders of both companies, after careful consideration, we have decided to withdraw our acquisition proposal given the reluctance of Allegro&#8217;s board of directors to fully engage and explore our proposal.&#8221;
ON Semiconductor said the company continues to see significant long-term opportunities in the automotive, industrial and AI data center markets.
ON Price Action: At publication time, <a href="http://benzinga.com/quote/on">ON Semiconductor shares</a> were up 2.47%, trading at $36.50 in Monday&#8217;s after-hours session, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44801373/a-us-recession-in-2025-betting-odds-say-its-more-likely-than-not">A US Recession In 2025? Betting Odds Say It&#8217;s More Likely Than Not</a></li>
</ul>
Photo: Shutterstock.

After-Hours Center

Movers

Tech

ALGM

ON Semiconductor Stock Jumps After Withdrawing Proposal To Acquire Allegro MicroSystems

<a href="https://www.globenewswire.com/Tracker?data=rYaB3AXtBTvABdXKuHrm2p72-FAIaLz-4-JrcxwiqDX9gbEF9W0Gcgwh5cwh0g-hG-BVBSCYGdYlXoyHuOO-f0zWEM_Wm9LkcAmN83CYQtwdbBQg-cPQeGzlbXR-zgJVRpJaig66knLkDOD8qKzm_Z2fGKb0-QotehA-U7CIr7oXl94vQLTOcvbYkjdV4kejzMNsX90vgwl0PbjZfJs3dws3tkIl4Ew9_P4e3lTcRhaL4ej2GmYyoNNy38knBpHnDM_lBCJScxQQq4jjTorBwEEYr9e7ZQlKuLCbQ3qgNe4gQRzjGHQiO46alSfSEiyXQnkzwJGk-QS7RAolIheMnt7xbpjn-7-tYilbVOwxVic4EqKvFDQwc4XJdNDIRbVscxHd-pggMTVTRROyqLWB1dGh1lnzqWZ08xNYronYBNoJ-p8k3h52-jb9vYVuEAj0M-bAQu_cYdp9rY5y2LW5C7PvRoa65Mui5OziwOcBPDJLQjGcrs2pCFYIWTZNDDRY">Cue Biopharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.
Oppenheimer &amp; Co. Inc. is acting as sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager for the offering.

Offerings

Cue Biopharma Announces Proposed Public Offering; No Size Or Amount Disclosed

<h3>Gainers</h3>
<ul>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) stock moved upwards by 6.7% to $0.15 during Monday's after-market session. The company's market cap stands at $9.1 million. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares moved upwards by 5.27% to $0.57. The company's market cap stands at $13.8 million. </li>
<li>Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) stock rose 4.98% to $6.95. The market value of their outstanding shares is at $690.5 million. </li>
<li>Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) shares moved upwards by 4.91% to $0.57. The market value of their outstanding shares is at $106.3 million. </li>
<li>Twin Hospitality Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) stock increased by 4.88% to $6.65. The market value of their outstanding shares is at $333.6 million. </li>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) shares moved upwards by 4.58% to $1.14. The market value of their outstanding shares is at $45.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) shares declined by 8.8% to $0.29 during Monday's after-market session. The market value of their outstanding shares is at $84.6 million. </li>
<li>Wah Fu Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) stock decreased by 7.7% to $1.32. The market value of their outstanding shares is at $5.8 million. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) stock declined by 7.58% to $0.24. The market value of their outstanding shares is at $11.0 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares decreased by 6.64% to $0.35. The market value of their outstanding shares is at $101.5 million. </li>
<li>MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) stock decreased by 4.9% to $93.06. The company's market cap stands at $10.2 billion. </li>
<li>Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares fell 4.79% to $0.24. The company's market cap stands at $18.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GROV

JDZG

LESL

MMYT

NWTN

TWNP

WAFU

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 7.83% to $0.34. The company's market cap stands at $19.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

BSGM

CRIS

GOVX

HCTI

KRYS

MCRB

NAOV

NERV

POCI

VERO

YCBD

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Techprecision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPCS#NASDAQ">TPCS</a>) stock moved upwards by 7.5% to $2.58 during Monday's after-market session. The company's market cap stands at $24.9 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) shares rose 6.14% to $1.21. The company's market cap stands at $10.7 million. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) stock moved upwards by 5.92% to $0.03. </li>
<li>Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock rose 5.85% to $20.25. The market value of their outstanding shares is at $9.1 billion. </li>
<li>GEE Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/JOB#AMEX">JOB</a>) stock moved upwards by 5.74% to $0.19. The market value of their outstanding shares is at $21.1 million. </li>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) shares rose 4.99% to $0.59. The market value of their outstanding shares is at $29.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>YY Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) shares fell 10.9% to $1.1 during Monday's after-market session. The market value of their outstanding shares is at $42.0 million. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) shares fell 5.68% to $0.5. The company's market cap stands at $15.7 million. </li>
<li>Roma Green Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) stock decreased by 5.67% to $1.0. The market value of their outstanding shares is at $15.5 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares fell 5.53% to $0.21. The company's market cap stands at $4.4 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock declined by 5.52% to $1.2. The company's market cap stands at $13.2 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock fell 5.33% to $0.37. The market value of their outstanding shares is at $35.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIR

HKPD

RKLB

ROMA

SUNE

TPCS

USEA

WLGS

YYGH

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) shares moved upwards by 62.5% to $1.04 during Monday's after-market session. The company's market cap stands at $27.4 million. </li>
<li>Xperi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>) shares rose 8.98% to $7.16. The company's market cap stands at $325.9 million. </li>
<li>Saiheat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) shares rose 8.04% to $4.43. The market value of their outstanding shares is at $7.5 million. </li>
<li>Ascent Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) shares increased by 7.46% to $1.44. The market value of their outstanding shares is at $2.4 million. </li>
<li>Foxx Development Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXX#NASDAQ">FOXX</a>) shares increased by 6.27% to $4.91. The market value of their outstanding shares is at $35.7 million. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) shares moved upwards by 5.73% to $0.15. The company's market cap stands at $1.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) shares decreased by 12.3% to $19.3 during Monday's after-market session. The company's market cap stands at $3.5 billion. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares declined by 11.87% to $0.66. The market value of their outstanding shares is at $1.2 million. </li>
<li>Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares declined by 10.99% to $4.78. The company's market cap stands at $1.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) shares decreased by 9.08% to $4.01. The market value of their outstanding shares is at $2.0 million. </li>
<li>AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) stock declined by 8.22% to $0.58. The company's market cap stands at $10.5 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock declined by 6.15% to $1.68. The market value of their outstanding shares is at $43.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLD

ARBB

ASTI

AUUD

BTOG

FOXX

LIDR

SAIH

XPER

12 Information Technology Stocks Moving In Monday's After-Market Session

As previously disclosed on the Form 8-K dated April 9, 2025,&nbsp;Primis Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) (the "Company"), submitted a hearing request ("Hearing Request") to The Nasdaq Stock Market LLC ("Nasdaq") appealing Nasdaq's delisting determination and requesting a stay of delisting of the Company's securities pending a final written decision by the Nasdaq Hearings Panel (the "Panel").
On April 10, the Company received a response letter from the Nasdaq Hearings Advisor setting the hearing for Thursday, May 15, 2025 and staying the delisting determination pending a final written decision by the Panel.
The Company plans to file the Form 10-K for the year ending December 31, 2024 as promptly as practicable and currently expects to do so prior to the hearing, at which point the Company will be in compliance with the Nasdaq Listing Rules.

FRST

Primis Financial Receives Receipt Of Stay From Nasdaq;  Company Received A Response Letter From The Nasdaq Hearings Advisor Setting The Hearing For Thursday, May 15, 2025

Citigroup analyst Andrew Kaplowitz maintains Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Buy and lowers the price target from $37 to $29.

Citigroup Maintains Buy on Symbotic, Lowers Price Target to $29

<ul>
<li>Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. &nbsp;</li>
<li>The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases. &nbsp;</li>
<li>The candidate compound has the potential to reach patients with autoimmune diseases earlier in their treatment journey and achieve long-term disease control by reducing targeted B cell populations. &nbsp;</li>
</ul>
INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.
Cue Biopharma's preclinical candidate molecule binds to a B cell specific membrane protein and in parallel selectively engages virus-specific memory killer T cells. This enables it to selectively deplete B cells and dampen autoimmune and inflammatory processes, potentially offering improved benefit and safety versus other therapeutic approaches targeting B cells.

Biotech

General

Cue Biopharma And Boehringer Ingelheim Announce Strategic Partnership To Develop And Commercialize First-in-Class Bispecific T Cell-Engaging B Cell Depletion Therapy CUE-501 For Autoimmune And Inflammatory Diseases, Aiming For Earlier Intervention And Long-Term Disease Control

Citigroup analyst Andrew Kaplowitz maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Buy and lowers the price target from $350 to $283.

Citigroup Maintains Buy on Rockwell Automation, Lowers Price Target to $283

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today announced it has been selected to provide hypersonic test launch capability with its HASTE launch vehicle, engineering expertise, and other services through its participation in two multi-billion dollar government development programs for the United States and the United Kingdom.
Rocket Lab has been selected by the U.S. Air Force to participate within its Enterprise-Wide Agile Acquisition Contract (EWAAC), a $46 billion indefinite delivery-indefinite quantity (IDIQ) contract designed for the rapid acquisition of innovative technologies, engineering services, and technical solutions that develop the Air Force's new capabilities. The program has a contracting period through to 2031 and is designed to be broad in scope, flexible in funding, and agile for maximum use to enable the Air Force to quickly procure services and technologies across various domains.
Further, Rocket Lab has also been selected by the United Kingdom's Ministry of Defence (UK MOD) for its Hypersonic Technologies &amp; Capability Development Framework (HTCDF), a ~$1.3 billion (£1 billion) framework to rapidly develop advanced hypersonic capabilities for the United Kingdom. As a newly-selected supplier to the HTCDF, Rocket Lab is now eligible to bid to provide services, technologies, and testing capabilities that support the UK's development of sovereign hypersonic technology.

Contracts

Rocket Lab Selected For U.S. Air Force's $46B EWAAC And UK's $1.3B Hypersonic Development Framework To Provide HASTE Launch Vehicle, Engineering Services, And Advanced Testing For Next-Gen Hypersonic Capabilities Through 2031

Across the recent three months, 4 analysts have shared their insights on Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Verve Therapeutics and provided 12-month price targets. The average target is $17.5, accompanied by a high estimate of $25.00 and a low estimate of $15.00. Witnessing a positive shift, the current average has risen by 14.75% from the previous average price target of $15.25.
<img src="https://www.benzinga.com/files/images/story/2025/1744664460_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Verve Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $25.00&#x7C;$15.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $15.00&#x7C;$15.00 &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $15.00&#x7C;$17.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $15.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Verve Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Verve Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Verve Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Verve Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VERV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Verve Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Verve Therapeutics</h2>
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
<h3>Breaking Down Verve Therapeutics's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Verve Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 154.28%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Verve Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -382.53% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -9.99%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Verve Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.63%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Verve Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VERV

Assessing Verve Therapeutics: Insights From 4 Financial Analysts

15 analysts have expressed a variety of opinions on Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.0, a high estimate of $16.00, and a low estimate of $8.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.04%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744664452_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Snap's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $9.50&#x7C;$13.50 &#x7C; 
&#x7C;Lloyd Walmsley &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $9.00&#x7C;$14.00 &#x7C; 
&#x7C;Thomas Champion &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $10.00&#x7C;$13.00 &#x7C; 
&#x7C;Justin Post &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $10.50&#x7C;$14.50 &#x7C; 
&#x7C;Doug Anmuth &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $8.00&#x7C;$10.00 &#x7C; 
&#x7C;Ken Gawrelski &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $9.00&#x7C;$11.00 &#x7C; 
&#x7C;Devin Ryan &#x7C;JMP Securities &#x7C;Lowers &#x7C;Market Outperform&#x7C; $14.00&#x7C;$16.00 &#x7C; 
&#x7C;Shyam Patil &#x7C;Susquehanna &#x7C;Raises &#x7C;Neutral &#x7C; $13.00&#x7C;$12.00 &#x7C; 
&#x7C;Doug Anmuth &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $10.00&#x7C;$11.00 &#x7C; 
&#x7C;Ronald Josey &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $13.50&#x7C;$13.00 &#x7C; 
&#x7C;Justin Post &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $14.50&#x7C;$14.00 &#x7C; 
&#x7C;Ken Gawrelski &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $11.00&#x7C;$15.00 &#x7C; 
&#x7C;David Turkaly &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $16.00&#x7C;$16.00 &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $16.00&#x7C;$16.00 &#x7C; 
&#x7C;Brian Pitz &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $16.00&#x7C;$18.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Snap. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Snap compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Snap's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Snap's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SNAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Snap analyst ratings.</a>
<h2>Discovering Snap: A Closer Look</h2>
Snap is a technology company best known for its marquis social media application Snapchat, a visual messaging application that has amassed hundreds of millions of users. The app was initially only used to communicate with family and friends through photographs and short videos (known as "Snaps"). Users can now enjoy augmented reality, or AR, lenses, content from famous creators and celebrities, updates about local events, and more. Although the app offers a paid subscription option with premium features, advertising sales produce most of the app's revenue. The firm also sells wearable devices called AR Spectacles, which can capture photos and videos overlayed with AR lenses, but these make up a small portion of Snap's overall sales.
<h3>Understanding the Numbers: Snap's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Snap's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 14.4%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Snap's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Snap's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.39%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Snap's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.12%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Snap's debt-to-equity ratio surpasses industry norms, standing at 1.73. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNAP

15 Analysts Assess Snap: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $383.75, a high estimate of $425.00, and a low estimate of $343.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.48%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744664444_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Valmont Industries by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Nathan Jones &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $343.00&#x7C;$425.00 &#x7C; 
&#x7C;Brent Thielman &#x7C;DA Davidson &#x7C;Maintains &#x7C;Neutral &#x7C; $380.00&#x7C;$380.00 &#x7C; 
&#x7C;Nathan Jones &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $425.00&#x7C;$387.00 &#x7C; 
&#x7C;Nathan Jones &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $387.00&#x7C;$382.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Valmont Industries. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Valmont Industries compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Valmont Industries's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Valmont Industries's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Valmont Industries analyst ratings.</a>
<h2>Unveiling the Story Behind Valmont Industries</h2>
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting and transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.
<h3>Breaking Down Valmont Industries's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Valmont Industries's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.14%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 7.49%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Valmont Industries's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 5.04%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Valmont Industries's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.27%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.56, Valmont Industries adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Valmont Industries: Insights From 4 Financial Analysts

Health Care

Press Releases

American Oncology Network Expands Radiation Oncology Services, Opens New Clinic

OTC Markets Group Welcomes American Oncology Network, Inc. to OTCQX

American Oncology Network Announces the Commencement of OTCQX Trading

Indianapolis Medical Oncologist Co-authors Research Presented at International Lymphoma Symposium

American Oncology Network Announces Second Quarter 2024 Earnings Release Date and Conference Call

Florida Oncology and Hematology and American Oncology Network Opens New Location in Cape Coral, Welcomes Medical Director, Dr. Van den Bergh, and Drs. Venkata Parsa, and Shivtaj Mann

Comments

American Oncology Network

Notizie

Ultime notizie per American Oncology Network (OTC:AONC) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO